SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05375084 |
Recruitment Status :
Recruiting
First Posted : May 16, 2022
Last Update Posted : February 16, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non Small Cell Lung Cancer Solid Tumor | Drug: BBP-398 with nivolumab | Phase 1 |
The primary objective for Phase 1a Dose Escalation is to evaluate the safety, tolerability, and RP2D of BBP-398, a SHP2 inhibitor, when used in combination with nivolumab in patients with advanced NSCLC with a KRAS mutation who have failed standard of care treatment.
The primary objective for Phase 1b Dose Expansion is to evaluate the antitumor activity of BBP-398, as defined by the ORR (per investigator) according to RECIST v1.1, when used in combination with nivolumab in patients with advanced NSCLC with a KRAS mutation who have failed standard of care treatment.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 45 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1 Study of the SHP2 Inhibitor BBP-398 (Formerly Known as IACS-15509) in Combination With the Programmed Death Receptor-1 Blocking Antibody Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation |
Actual Study Start Date : | October 20, 2022 |
Estimated Primary Completion Date : | July 2024 |
Estimated Study Completion Date : | January 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Dose Escalation Level 1
Level 1 oral capsules administered in combination with nivolumab
|
Drug: BBP-398 with nivolumab
BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks) |
Experimental: Dose Escalation Level 2
Level 2 oral capsules administered in combination with nivolumab
|
Drug: BBP-398 with nivolumab
BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks) |
Experimental: Dose Escalation Level 3
Level 3 oral capsules administered in combination with nivolumab
|
Drug: BBP-398 with nivolumab
BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks) |
Experimental: Dose Expansion
RP2D defined dose. Oral capsules administered in combination with nivolumab
|
Drug: BBP-398 with nivolumab
BBP-398 administered orally once a day (QD); nivolumab administered intravenously every 4 weeks (Q4wks) |
- Phase 1a Dose Escalation: Assess safety, tolerability, and recommended phase 2 dose (RP2D) of BBP-398 in combination with nivolumab [ Time Frame: Completion of 1 Cycle (28 days) ]
- Phase 1b Dose Expansion: Assess antitumor activity of BBP-398 in combination with nivolumab [ Time Frame: Completion of 1 Cycle (28 days) ]Anti-tumor activity will be defined by objective response rate (ORR) according to RECIST v1.1
- Assess preliminary antitumor activity of BBP-398 in combination with nivolumab [ Time Frame: Completion of 1 Cycle (28 days) ]Anti-tumor activity will be defined by objective response rate (ORR) [escalation], duration of response (DOR) and progression free survival (PFS), as defined by RECIST v1.1. and overall survival (OS) [both escalation and expansion]
- Phase 1b Dose Expansion: Assess safety and tolerability of BBP-398 at the RP2D, in combination with nivolumab [ Time Frame: Completion of 1 Cycle (28 days) ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
- Patients must have histologically documented, locally advanced and unresectable, or metastatic NSCLC with documentation of a KRAS mutation within the 1 year prior to screening.
- Patients must have measurable disease by RECIST v1.1.
- Patients must have a minimum life expectancy of >12 weeks after start of study treatment.
- Patients must have progression or disease recurrence on or after at least one prior line of systemic therapy, which must include platinum-based doublet chemotherapy and anti-PD-(L)1 therapy.
- Patients must have experienced progressive or recurrent disease occurring either during treatment or within 90 days after discontinuing anti-PD-(L)1 therapy.
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.
- Patients must have adequate organ function.
Key Exclusion Criteria:
- Patients that have participated in an interventional clinical study within the last 4 weeks.
- Patients that have received radiotherapy or proton therapy with a limited field of radiation for palliation within 1 week of the start of study treatment, OR radiation to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the start of study treatment.
- Patients with known central nervous system (CNS) tumors or active CNS metastases.
- Patients that have experienced progressive disease (PD) within the first 120 days of initiating treatment with an anti- PD-(L)1 agent (e.g., primary refractory).
- Patients that have a history of allogenic bone marrow transplant.
- Patients that have select known or suspected autoimmune disease.
- Patients that have a condition requiring systemic treatment with either corticosteroids (>10 mg prednisone equivalent) or other immunosuppressive medication within 14 days of study start.
- Patients that have received any live/attenuated vaccine within 30 days of first study treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05375084
Contact: Navire Clinical Operations | 650-391-9740 | NAV1004ct.gov@bridgebio.com |
United States, Arkansas | |
Highlands Oncology | Recruiting |
Springdale, Arkansas, United States, 72762 | |
Contact: Allie Clemons 479-872-8130 research@hogonc.com | |
Principal Investigator: Eric S Schaefer, MD | |
United States, California | |
Scripps Clinic Torrey Pines | Recruiting |
La Jolla, California, United States, 92037 | |
Contact: Kiley Borchard, CCRC crs_leadership_research@scrippshealth.org | |
Principal Investigator: Michael Kosty, MD | |
Providence Medical Foundation | Recruiting |
Santa Rosa, California, United States, 95403 | |
Contact: Tracy Foster 707-521-3830 tracy.foster@stjoe.org | |
Principal Investigator: Ian Anderson, MD | |
United States, Florida | |
Memorial Regional Hospital (Memorial Cancer Institute) | Recruiting |
Hollywood, Florida, United States, 33021 | |
Contact: Tamara Quintana 954-265-4325 lraez@mhs.net | |
Contact: Milton Sanchez | |
Principal Investigator: Luis E Raez, MD | |
Moffitt Cancer Center | Recruiting |
Tampa, Florida, United States, 33612 | |
Contact: Eduardo Galvez 813-745-4673 Eduardo.Galvez@moffitt.org | |
Principal Investigator: Bruna Pellini, MD | |
United States, Maryland | |
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | Recruiting |
Baltimore, Maryland, United States, 21224 | |
Contact: Kayla Eck 410-955-7458 kmarron1@jhmi.edu | |
Principal Investigator: Kristen Marrone, MD | |
United States, Michigan | |
Henry Ford Hospital | Recruiting |
Detroit, Michigan, United States, 48202 | |
United States, New York | |
Roswell Park Cancer Institute | Recruiting |
Buffalo, New York, United States, 14203 | |
United States, Ohio | |
Cleveland Clinic | Recruiting |
Cleveland, Ohio, United States, 44195 | |
Contact: Jessica Grebenc 216-444-7923 canceranswer@ccf.og | |
Principal Investigator: Nathan Pennell, MD, PhD | |
United States, Oregon | |
Providence Portland Medical Center | Recruiting |
Portland, Oregon, United States, 97213 | |
Contact CanRsrchStudies@providence.org | |
Principal Investigator: Rachel Sanborn, MD | |
United States, Pennsylvania | |
University of Pennsylvania (Abramson Cancer Center) | Recruiting |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, South Carolina | |
Medical University of South Carolina (MUSC) - Hollings Cancer Center | Recruiting |
Charleston, South Carolina, United States, 29425 | |
United States, Texas | |
MD Anderson Cancer Center | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Lamiae Sahnoune 832-729-2342 Lsahnoune@mdanderson.org | |
Principal Investigator: Marcelo V Negrao | |
Millennium Research and Clinical Development | Recruiting |
Houston, Texas, United States, 77090 | |
United States, Virginia | |
NEXT Oncology | Recruiting |
Fairfax, Virginia, United States, 22031 | |
Contact: Blake Patterson 703-783-4510 bpatterson@nextoncology.com | |
Principal Investigator: Alex Spira |
Responsible Party: | Navire Pharma Inc., a BridgeBio company |
ClinicalTrials.gov Identifier: | NCT05375084 |
Other Study ID Numbers: |
NAV-1004 |
First Posted: | May 16, 2022 Key Record Dates |
Last Update Posted: | February 16, 2024 |
Last Verified: | February 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
KRAS mutation MAPK-pathway alterations NSCLC SHP2 |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases |
Carcinoma, Bronchogenic Bronchial Neoplasms Nivolumab Antineoplastic Agents, Immunological Antineoplastic Agents Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action |